Pharmaceutical News and Articles

Polysubstance, Opioid-Related Overdose Deaths Rose From 2004 to 2022

Overdose deaths from polysubstance use escalated from 2004 to 2022 for all racial and ethnic groups but with disproportionate increases for non-Hispanic Black a

Naloxone Has Limitations for Reversing ODs From Fentanyl, Sufentanil

Naloxone has limitations for reversing overdoses from fentanyl and sufentanil, gradually reversing respiratory depression, but with variable reversal times, acc

Study Looks at CRC Risk, Non-CRC Mortality in Seniors With Prior Adenoma

Older adults with adenoma at prior colonoscopy are more likely to experience subsequent colorectal cancer (CRC), but the cumulative risks are exceeded by compet

Ifinatamab Deruxtecan Granted Priority Review in the U.S. for Adult Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer who Experienced Disease Progression on or After Platinum-Based Chemotherapy

Daiichi Sankyo (TSE 4568) and Merck s (NYSE MRK), known as MSD outside of the United States and Canada, Biologics License Application (BLA) for ifinatamab derux

Lilly's Jaypirca (pirtobrutinib) Significantly Extended Progression-Free Survival When Added to a Venetoclax Time-Limited Regimen in Patients with Previously Treated CLL/SLL

Eli Lilly and Company (NYSE LLY) today announced positive topline results from the Phase 3 BRUIN CLL-322 trial of Jaypirca (pirtobrutinib), a non-covalent (reve

Astellas Doses First Patient in Phase 3 Study of Setidegrasib (ASP3082) for KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma

TOKYO, April 15, 2026 Astellas Pharma Inc. (TSE 4503, President and CEO Naoki Okamura, Astellas ) today announced that the first patient has been successfully d

ESCMID: Sanofi’s NUVAXOVID™ COVID-19 Vaccine Showed Better Tolerability Than mNEXSPIKE in Head-to-Head Study

Paris, April 18, 2026. Sanofi s protein-based, non-mRNA COVID-19 vaccine NUVAXOVID (COVID-19 Vaccine, Adjuvanted) demonstrated statistically significant lower s

Travere Therapeutics Announces Full FDA Approval of Filspari (sparsentan), the First and Only Approved Medicine for Focal Segmental Glomerulosclerosis (FSGS)

Cumberland Pharmaceuticals Announces Expanded Indication for Caldolor (ibuprofen) Injection

New Clues Explain Why Immunotherapy Fails in Pancreatic Cancer

SUNDAY, April 19, 2026 Immunotherapy has largely failed as a treatment for cancer of the pancreas, and researchers have zeroed in on a key reason.Pancreatic tum